Dr. Anseth was born and raised in Montana. He attended Concordia College and the University of North Dakota School of Medicine. He completed an orthopedic surgery residency in Flint, MI and a fellowship in Adult Reconstruction in La Jolla, CA. Dr. Anseth joined Twin Cities Orthopedics in 2005. He currently leads the Total Joint Service Line. During his time with TCO, Dr. Anseth has helped develop joint replacement centers and bundled payment programs. As the Total Joint service line lead, he is part of the team evaluating new technologies in joint replacement to understand the benefits as well as the risk.

• Medtech MVP

Maria Berkman, MD, MBA, is a Director, and Head of the MedTech practice at Broadview Ventures where she manages the firm’s MedTech investment strategy and activity, from identification and screening of new opportunities through due diligence, negotiation of deal structure, portfolio company board involvement, and overall portfolio strategy. Maria currently serves on the boards of Alleviant Medical, Aria CV, AtaCor, FineHeart, RapidPulse, Vascular Graft Solutions, and Vectorious Medical Technologies, and previously served on the boards of Lyra Therapeutics (NSDQ:LYRA), Apama Medical (acquired), Remedy Therapeutics (acquired), and Capricor (NSDQ:CAPR). Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group, where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercial strategy and competitive strategic planning for BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned a concurrent MD from the UCLA School of Medicine and MBA from the Anderson School of Management at UCLA, graduating Alpha Omega Alpha. Outside of Broadview, Maria serves as a VC Mentor for the UCLA Biodesign Fellowship, Life Science Committee member at the Boston Museum of Science, member of the AdvaMed MedTech Investment Working Group, and Co-Chair of the NEVCA MedTech Academy; Maria previously served as an SBIR/STTR grant reviewer for the National Science Foundation and as a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.

• Medtech MVP

Joe is a Managing Partner at 3x5 Partners, a venture capital firm that collaborates with passionate entrepreneurs who are developing solutions in response to global healthcare and climate needs. Previously, Joe was a Managing Director at SightLine Partners, where he helped raise $250M+ over 15 years to invest in the healthcare sector. During his tenure at Sightline, Joe served on numerous boards and completed transactions in over 50 companies with his partners. He began his career at Bremer Asset Management and is based in the Twin Cities.

• Medtech MVP

Andrew J. Danielsen serves as chair of Mayo Clinic Ventures in the Department of Business Development at Mayo Clinic, where he oversees the licensing, technology development, venture investment and business development functions. Collectively, these groups work to identify, develop and commercialize Mayo Clinic intellectual property. These activities generated over $100 million in revenue for Mayo Clinic in 2020. Prior to joining Mayo Clinic Ventures in 2002, Mr. Danielsen conducted research at Mayo Clinic where he worked to identify therapeutic targets in breast and ovarian cancer. Mr. Danielsen serves on several committees throughout Mayo Clinic, including the Executive Subcommittee of the Medical-Industry Relations Committee. He is also a member of multiple groups responsible for funding innovative new technologies or startup companies, including the Mayo Clinic Venture Fund Investment Committee, the Discovery Translation Program, and the Department of Business Development Investment Committee. Mr. Danielsen received his B.S. in biochemistry and molecular biology from the University of Wisconsin-Eau Claire and his M.S. in molecular biology from Mayo Clinic Graduate School of Biomedical Sciences.

• Medtech MVP

James joined Santé Ventures in 2009 and is an emergency medicine physician. Prior to joining Santé, James served in the Air Force and was Vice-Chair of Emergency Medicine at Wilford Hall Medical Center, an academic level-one trauma center. He completed two tours in Iraq as a Critical Care Transport Team Chief and Emergency Department Commander, before separating honorably as a Major in 2008. James is an Oversight Committee member for the University of Michigan’s Michigan Translational Research & Commercialization program, an early-stage granting body for life science companies. He is also a Mentor in the Coulter Program at Michigan and a Board Member of the Michigan Center for Integrative Research in Critical Care. James is board-certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital. He earned his MD from the Harvard–MIT Program in Health Sciences and Technology (HST), his MBA from the University of Texas McCombs School of Business and his BS in bioengineering from the University of Michigan.

• Medtech MVP

Morgan Evans is an engineer by training, an entrepreneur by nature, and an executive by necessity. With nearly two decades’ experience in the full lifecycle of MedTech product development and delivery - from idea through regulatory approval to commercialization - she works from first-hand knowledge of how to conceive and design technically complex and highly regulated products, attract talent and build teams, and establish sustainable companies. The throughline in Morgan’s MedTech career is an iterative style of problem-solving that focuses one eye on the immediate task, and the other eye on how a process can be improved. Needing technical expertise for her own product development, Morgan built a network of collaborators that continues to work together through AVIO Medtech Consulting. Finding high age and gender hurdles to her early effort to raise funds, she found partners with whom to form Engage Venture Partners to open doors to angel and early series investors for entrepreneurs, and to make direct investments using special purpose investment vehicles that provide flexibility and collaborative due diligence. She remains a hands-on leader in an innovative medical device company — Agitated Solutions, Inc (ASI). ASI’s initial product received its first regulatory clearance in early 2024. ASI has a portfolio of new products in the development and regulatory pipeline. Morgan is involved in a variety of organizations and forums exploring MedTech development, women’s business leadership, and entrepreneurial activity. As a nearly lifelong basketball player and coach, Morgan volunteers with school teams in her home community, as well as with AAU summer programs. But that’s just for the sheer joy of it.

• Medtech MVP

Virginia is Vice President of Exploration at Edwards Lifesciences, where she builds external partnerships globally to advance breakthrough innovation. She has a track record of delivering innovation to patients, with roles spanning medical device, pharmaceutical and nutrition businesses. Virginia has focused on advancing innovation, with R&D, Program Management, and Business Development leadership roles at Stryker, Abbott, and Johnson & Johnson. She chairs the Cornell Biomedical Engineering Advisory Council, is an AIMBE Fellow, and is a co-founder of MedtechWomen. She holds B.S. and M.Eng. degrees in Mechanical Engineering from Cornell and a Ph.D. in Mechanical Engineering from Stanford.

• Medtech MVP

Change your story, change your world.

My story? I hang out with smart people who save lives, and if I do my job well, they save more lives.

20 years at the Medical Alley Association leading industry wide efforts to transform the industry including the creation of the Medical Device Innovation Consortium, securing over a billion dollars of international investment in Minnesota, and launching Medical Alley Starts, a global venture platform supporting early-stage innovators.

But more importantly, I'm a patient who benefits from the work YOU do. If you need help, I'm there.

• Medtech MVP

No bio available.

• Medtech MVP

David has 25 years of healthcare experience evaluating Medical Device, Life Science Tool, Diagnostic and Digital Health companies and advising boards on strategic and financial direction. Prior to founding Gilmartin Capital, David was a Managing Director at Morgan Stanley and Head of Morgan Stanley’s medical technology equity research practice for the last 15-years. He was a top ranked analyst at Morgan Stanley and in the Institutional Investor (II) Medical Supplies & Devices annual poll. Before joining Morgan Stanley, David was a partner and top ranked medical technology analyst at Thomas Weisel Partners and a founding member of the healthcare practice. David received a BA in healthcare policy with honors from the University of Pennsylvania. David serves as an advisor to Equalize Health, a non-profit that is developing medical devices for underserved populations. He lives outside of San Francisco with his wife Lynn, daughter Olivia, son Jack, and dog Tucker. David is a struggling guitar player, recovering a cappella singer, and he loves the mountains in any season.

• Medtech MVP

My mission is to help people live longer and feel better focused on arrhythmias (Atrial Fibrillation). I'm seeking to amplify that impact by adding artificial intelligence (AI) to my skill set. My tools are innovation blending engineering, medicine, and business insights that I gained through diverse experiences and education. Since college, I have strived to learn about cardiac electrophysiology in the broadest sense—medicine, clinical trials, regulatory pathways, engineering, and the business. I started as an electrical engineer working on a wireless EKG at MIT. Seeing how it helped patients inspired me to go to medical school and become a cardiac electrophysiologist. I’m licensed to practice medicine in Minnesota, Washington DC, Virginia, Ohio, and California. After training at Mayo, I worked in an academic practice for 6 years. I started-up 2 companies and then spent 9 years in the medical device industry. While my passion is electrophysiology, I have worked in multiple areas of cardiology. I have been credited with 14 patents in the space, which generates $2B in revenue and touches 500K patients a year. I am unapologetic about challenging accepted wisdom. An example includes disproving that lesions have to be transmural to get isolation around the pulmonary veins. This insight led to the understanding of High Power Short Duration Ablation, which became a core organizational competitive differentiator for St. Jude. I am a constant learner and every year try to learn a new skill (piano and golf are examples). Because I have found the greatest innovation comes from the intersection of fields, I have sought new work experiences in adjacent fields to medical device. Most recently, I was the Chief Strategy Officer at a state-wide $6B hospital system. This helped me better understand the challenges hospitals face and how they make decisions. It also exposed me to diverse fields like neurology and cell therapy, which could potentially help in arrhythmia care. During my 2-years as a hospital administrator, I realized that arrhythmia care could vary depending on which doctor you saw. Much of therapy is heuristic and image based. At the same time, I was learning more about AI and thought AI would be a great way to equalize care of arrhythmias. At Neutrace, we seek to give every arrhythmia patient world-class care.

• Medtech MVP

Michael “Mike” Mahoney is Chief Executive Officer of Boston Scientific Corporation and Chairman of the company’s Board of Directors. Boston Scientific is a global medical technology leader with approximately $12.7 billion in annual revenue and commercial representation in more than 130 countries. Under Mike’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 45,000 global employees reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation and urology, and women’s health. Since joining Boston Scientific, Mike has focused the company on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value to its shareholders. Mike’s career spans more than 25 years of success building market-leading medical device, capital equipment and healthcare IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson. Prior to joining Johnson & Johnson, Mike was President and Chief Executive Officer of Global Healthcare Exchange (GHX). For the first 12 years of his career, Mike advanced through a series of leadership roles at General Electric Medical Systems, including General Manager of the company’s Healthcare Information Technology business. Mike serves on the Board of Directors of Baxter International, the Board of Boys & Girls Club of Boston and as the chair of the Board of Governors of Boston College CEO Club. He earned his B.B.A. in Finance from University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.

• Medtech MVP

Juan-Pablo Mas is a Partner at Action Potential VC, a bioelectronic medicine fund founded by GlaxoSmithKline, and is based in Santa Cruz, CA. He represents APVC on the Boards of Cala Health, Exo Imaging, Neuspera Medical, Presidio Medical, Saluda Medical, SetPoint Medical, Onc.AI and previously CVRx. Prior to APVC, he was an investor at Lightstone Ventures and Morgenthaler Ventures, where he was a Board observer at Ardian, Twelve, Nuvaira, Cabochon, and Miramar Labs. Prior to investing, Juan-Pablo led R&D and Strategy teams in Medtronic’s CardioVascular Division and was a member of the Global Brand Strategy team at Eli Lilly. Juan-Pablo earned an MBA from the Stanford Graduate School of Business as a Bonini Fellow, an MS in Electrical Engineering from Stanford University, and a BS in EE from the University of Massachusetts. He now serves on the Oversight Committee for Stanford’s Wu Tsai Neuroscience Institute, the Advisory Board for UCSF’s Rosenman Institute, the DEI Advisory Committee for RockHealth.org, and is a co-founder of the non-profit LatinxVC which is dedicated to increasing diversity within venture capital. Juan-Pablo is originally from Puerto Rico and played Division I men’s lacrosse at UMass.

• Medtech MVP

No bio available.

• Medtech MVP

Jeff joined OrbiMed as a Venture Partner in 2018 and currently serves as the Founder and Chief Executive Officer of evanesce Medical. Jeff has over 25 years of medical device experience with executive and strategic roles in companies including Cardialen, ev3 (now Medtronic), Anulex, and Boston Scientific; and financial investment and analysis roles at Black River Asset Management, Foundation Medical, and Dain Rauscher Wessels. Jeff received his B.S. and M.B.A. from the University of Minnesota.

• Medtech MVP

Stacey Pugh is the Chief Commercial Officer at Butterfly Network. As a leader in Medical Technology, she has more than 20 years of experience in medical device research, development and commercialization. Stacey joined Butterfly in 2021 and will lead the company in the planning, organization, and implementation of all sales and marketing activities. Prior to Butterfly, Stacey was President of Medtronic’s Neurovascular Operating Unit, where she provided overall global strategic leadership, guided marketing and business development and was responsible for revenue growth. Prior to this role, Stacey was Vice President and General Manager of Neurovascular & Cerebral Spinal Fluid (CSF) businesses and was responsible for leading the company’s European, Middle Eastern and African (EMEA) business programs and developing trade strategies to support the global revenue and market share growth of Medtronic Neurovascular products. In addition, Stacey held various leadership roles in Covidien’s Neurovascular division as Vice President of Global Medical Affairs where she provided strategic direction for all medical affairs activities and executed strategic market access plans. As a registered nurse, Stacey spent the early years of her career in research, critical care and trauma nursing, and nursing education.

• Medtech MVP

Karen Ruszkoski is a seasoned medical device professional with two decades of experience in market access, health economics, marketing, and reimbursement. Karen is currently the Vice President of Market Access and Reimbursement at Volta Medical. Throughout her career, she has worked with leading organizations including Boston Scientific, St. Jude Medical, and Abbott. Karen is a passionate advocate for public health, specifically ensuring all patients have access to innovative technologies. She is skilled at developing evidence generation plans to support value propositions for various stakeholders, including governments, payers, hospital administrators, and physicians. Karen has also successfully influenced reimbursement decisions, including coding, coverage, and payment, for new technologies. Karen holds a B.S. in health management and policy from the University of New Hampshire. She also has a master’s in public health from the University of Michigan. Additionally, she is a certified professional medical coder from the American Academy of Professional Coders.

• Medtech MVP

Amrinder Singh is a Partner at Vensana Capital and joined the firm in 2021. Amrinder has nearly two decades of medtech operating and investing experience, ranging from engineering, corporate strategy, and venture capital investing. Prior to Vensana Capital, Amrinder was a Senior Investment Director at Medtronic Ventures where he supported new investments in the medtech and digital health spaces, providing operational and board management support to portfolio companies. Prior to his investment career, Amrinder led Business Development & Strategy for Medtronic’s care management services, helping to shape the vision for Medtronic's value-based healthcare strategy. Amrinder started his career at Medtronic within the Corporate Strategy group. Before joining Medtronic, Amrinder held product management and engineering positions at Thoratec Corporation. Amrinder graduated from University of California, Davis in Biosystems Engineering and earned his MBA from Northwestern University, Kellogg School of Management.

• Medtech MVP

Kelly Wei, Ph.D., is a visionary leader and innovation strategist with deep expertise in med-tech and business transformation. As Vice President of Corporate Strategy at Medtronic, she drives enterprise strategy, shaping portfolio priorities across operating units. Previously, she led Medtronic’s internal startups as Vice President of New Therapies and served as General Manager of Kanghui Orthopedics. With 60+ patents, Kelly has spearheaded groundbreaking advancements in neuromodulation, robotics, orthopedics, cardiology, and bioelectronic medicine. Her career spans R&D, general management, business development, and board governance. She is known for building high-performance teams through purpose, accountability, and psychological safety. A trusted advisor to corporate leaders, investors, and boards, Kelly leverages her business, technology, and people skills to drive meaningful innovation that transforms lives.

• Medtech MVP

Lisa Wipperman Heine currently serves on the Board of Directors for several public, private equity, and early-stage, VC-backed medtech/biotech companies. In addition, she has held executive leadership roles in both large medtech companies as well as venture-backed start-ups. Most recently, Lisa was President and Chief Executive Officer at preCARDIA, Inc., an early-stage, heart failure-focused medtech company which was acquired by Abiomed, Inc., in 2021. Ms. Heine also previously served in multiple leadership roles at ev3 and Covidien, Inc., including Global Vice President of Medical Affairs for Vascular Therapies. During her tenure at Covidien, she helped drive the strategy in support of a $1.7B business and was also responsible for leading the strategy and operations of Clinical Affairs, Healthcare Economics, Policy and Reimbursement, and Medical Education functions. Lisa’s current roles include serving as an independent director for Surmodics, Inc. (NASDAQ: SRDX), Miromatrix (NASDAQ: MIRO) and Gradient Denervation Technologies. She also previously served on the board of Natus Medical (NASDAQ: NTUS) which was acquired by the Archimed Group in 2022.

• Medtech MVP

Sarah is the founder and CEO of Melodi Health, a women’s health focused medical device company partnered with Medtronic to address profound unmet needs for women experiencing breast cancer and related surgical complications. Prior to Melodi, Sarah was a consultant to large multi-national companies helping to develop their R&D pipelines through immersive ethnographic and preclinical research. She began her career in medical device product development at Guidant in 2003 after receiving her degree in Chemical Engineering and Polymer Science from the University of Minnesota and has experienced all aspects of product development throughout her career from concept generation to post-market monitoring. She is passionate about applying her technical degree to practical health issues, particularly in women’s health.

• Medtech MVP

Darshana is a Founder and Managing Partner of Catalyst Health Ventures (CHV). She is actively involved in all aspects of fund management including investments and capital raising and has led several investments in the medical device, women’s health and diagnostics markets. She led CHV’s investments in Augmenix (acquired by Boston Scientific), nVision Medical (acquired by Boston Scientific), Maxwell Health (acquired by SunLife), Aria CV, PanTher Therapeutics, AtaCor Medical, Instylla, Avive and Rejoni. She currently (or previously) represents CHV on the Boards of all companies. Prior to joining CHV in 2007, Darshana was an Investigator at Vertex Pharmaceuticals, and an integral part of drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company and at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles. Darshana currently serves as an advisor of the Deshpande Center for Technological Innovation at MIT, (a foundation that helps MIT students and faculty commercialize breakthrough technologies and inventions), as a Board Director of The New England Venture Capital Association (NEVCA) and as a lead advisor to the Portfolia FemTech fund (an investment fund designed for women). Darshana received an M.P.A. from Harvard University, an M.A. in Cell and Molecular Biology from Boston University, and a B.S. in Biochemistry from Bombay University in Bombay, India.

• Medtech MVP